ICML 2019 | Autologous or allogeneic stem cell transplant for consolidation therapy in T-cell lymphomas?


During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Olivier Tournilhac from Clermont-Ferrand University Hospital, Clermont-Ferrand, FR, about whether autologous or allogeneic stem cell transplant should be used as consolidation for T-cell lymphomas.

Olivier Tournilhac discussed the multicenter AATT trial, which addressed the first-line treatment of peripheral T-cell lymphoma. Over the period of 3 years, 104 patients were enrolled, with the main aim to improve event-free survival by 25%, with final results showing no improvement using allogeneic transplantation compared with autologous transplantation.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF